Back to top

cell-therapy: Archive

Zacks Equity Research

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

AMRNNegative Net Change IOVAPositive Net Change INDVPositive Net Change